Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(01): 49-52
DOI: 10.4103/0971-5851.51445
Selected Summary

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation

Aarti Gupta
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110029, India
,
Lalit Kumar
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
07 March 2022

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med. 1997;336:1202-7.
  • 2 Sanchorwala V, Skinner M, Quillen K. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.
  • 3 Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-42.
  • 4 Comenzo RL, Vosburgh E, Simms et al. Doseintensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6.
  • 5 Comenzo RL, Vosburgh E, Falk RH. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-70.
  • 6 Gertz MA, Lacy MQ, Dispenzieri A et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113:549-55.
  • 7 Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3.
  • 8 Skinner M, Sanchorawala V, Seldin DC et al. Highdose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
  • 9 Porrata LF, Gertz MA, Litzow MR et al. Clin Cancer Res. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005;11:1210-8.
  • 10 Leung N, Leung TR, Cha SS et al. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005;106:3353-7.
  • 11 Seldin DC, Anderson JJ, Skinner M et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006;108:3945-7.
  • 12 Goodman HJ, Gillmore JD, Lachmann HJ et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006;134:417-25.
  • 13 Perfetti V, Siena S, Palladini G et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 2006;91:1635-43.
  • 14 Perz JB, Rahemtulla A, Giles C et al. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2006;37:937-43.
  • 15 Vesole DH, Pιrez WS, Akasheh M et al. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006;81:880-8.